CRBC News
Culture
Society
Security
Health
Conflict
Science
Technology
Politics
Environment
Lifestyle
Economy

Nanoparticles Repair the Blood–Brain Barrier and Reverse Alzheimer’s Signs in Mice

Researchers at IBEC and West China Hospital developed supramolecular nanoparticles that mimic ligands for the LRP1 receptor to repair the blood–brain barrier and accelerate amyloid‑beta clearance. In mice engineered to overproduce amyloid‑beta, three injections reduced toxic protein levels by 50–60% within an hour and restored cognitive performance over subsequent months. Published in Signal Transduction and Targeted Therapy, the study suggests restoring vascular clearance — not just targeting neurons — as a promising avenue for Alzheimer’s treatment. Human trials and extensive safety testing are still needed.

12:14 AM, 11/30/2025Science
Nanoparticles Repair the Blood–Brain Barrier and Reverse Alzheimer’s Signs in Mice

Researchers at the Institute for Bioengineering of Catalonia (IBEC) and West China Hospital Sichuan University report a promising nanotechnology approach that restores brain function and reduces Alzheimer’s-like pathology in mice by repairing the blood–brain barrier and accelerating removal of toxic proteins.

How the treatment works

The team engineered supramolecular nanoparticles that act as the therapy itself rather than as drug carriers. These particles mimic natural ligands that interact with the LRP1 receptor, a key regulator of transport across the blood–brain barrier and of amyloid‑beta clearance. After injection, the nanoparticles bind amyloid‑beta, cross the blood–brain barrier, and stimulate vascular clearance mechanisms that funnel the toxic protein into the bloodstream for disposal.

Study results

In mice genetically modified to overproduce amyloid‑beta, three injections of the nanoparticles reduced toxic protein levels by roughly 50–60% within an hour. Treated aging mice also showed substantial recovery of cognitive performance over the following months. The work was published in Signal Transduction and Targeted Therapy.

Why this approach matters

Unlike therapies that target neurons or directly attack amyloid plaques (for example, some antibody treatments), this strategy aims to rejuvenate the brain’s natural clearance system by repairing the vascular gatekeeper — the blood–brain barrier. Restoring vascular health and clearance pathways could offer a more sustainable and potentially safer route to slowing or reversing neurodegeneration.

Caveats and next steps

These findings are preliminary and limited to animal models. Translation to humans requires extensive preclinical safety testing and clinical trials to confirm efficacy, dosing, delivery, and long-term effects. Potential challenges include immune responses, differences between mouse and human brain vasculature, and ensuring the treatment is safe for older patients who often have multiple health conditions.

Nonetheless, the study opens a compelling new direction in Alzheimer’s research by highlighting vascular repair and clearance mechanisms as therapeutic targets. Further work will determine whether this nanotechnology approach can move from laboratory mice to human patients.

Similar Articles

Trending